Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| QN QNCXQuince Therapeutics | $33.93+5.7% | $34.5M | 13 assetsPhase 2b | Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor)Phase 2 · Data readout | |
| QN QNRXQuoin Pharmaceuticals | $5.57+7.1% | $11.2M | 6 assetsStage unavailable | No dated catalyst | |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| QT QTTBQ32 Bio |
| $15.97+0.7% |
| $475.4M |
4 assetsPhase 2a |
Bempikibart (ADX-914) Phase 2a · Data readout |
| QU QUREUniqure NV | $48.37-1.1% | $3.36B | 5 assetsPhase 1/2 | AMT-260Phase 1/2 · Data readout |
| RA RAINRain Oncology Inc. | $0.85+2.7% | $9.9M | 4 assetsStage unavailable | No dated catalyst |
| RA RANIRani Therapeutics | $0.88+3.4% | $123.7M | 3 assetsStage unavailable | No dated catalyst |
| RA RAPPRapport Therapeutics Inc | $48.24+0.8% | $2.31B | 6 assetsPhase 2 | RAP-219Phase 2 · Data readout |
| RA RAPTRAPT Therpaeutics | $58.02+0.0% | $1.68B | 5 assetsStage unavailable | No dated catalyst |
| RA RAREUltragenyx Pharmaceutical Inc. | $25.83+2.0% | $2.55B | 9 assetsApproved | UX111 (ABO-102)PDUFA · Approval decision |
| RC RCKTRocket Pharmaceuticals | $3.51+0.9% | $385.3M | 7 assetsApproved | No dated catalyst |
| RC RCUSArcus Biosciences | $30.34+2.8% | $3.82B | 27 assetsPhase 3 | Casdatifan + CabozantinibPhase 1 · Data readout |
| RD RDHLRedHill Biopharma | $0.63+0.8% | $3.8M | 15 assetsStage unavailable | No dated catalyst |
| RE REGNRegeneron Pharmaceuticals | $834.04+0.9% | $85.87B | 36 assetsApproved | CemdisiranPDUFA · Approval decision |
| RE REPLReplimune Group Inc | $14.77+5.1% | $1.39B | 11 assetsPhase 2/3 | RP2 in comb w/ atezolizumab and bevacizumabPhase 2 · Data readout |
| RE RETAReata Pharmaceuticals | $172.36+0.0% | — | 5 assetsStage unavailable | No dated catalyst |
| RE REVBRevelation BioSciences | $1.09+0.0% | $4.3M | 2 assetsStage unavailable | No dated catalyst |
| RF RFLRafael Holdings Inc | $2.16+16.8% | $112.3M | 6 assetsPhase 3 | Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin)Phase 3 · Data readout |
| RG RGNXRegenxbio | $10.72-3.1% | $707.7M | 8 assetsPhase 3 | ABBV-RGX-314 (Subretinal Delivery)Phase 3 · Data readout |
| RH RHHBYRoche Holding | $58.10+1.5% | $370.34B | 61 assetsPDUFA | Tecentriq/Atezolizumab (PD-L1 Antibody)PDUFA · Approval decision |
| RI RIGLRigel Pharmaceuticals | $45.89+1.4% | $857.2M | 13 assetsPhase 1b | R289Phase 1b · Data readout |
| RL RLAYRelay Therapeutics | $19.44-1.3% | $4.26B | 8 assetsPhase 1/2 | RLY-2608 + fulvestrant + ribociclib (triplet)Phase 1/2 · Data readout |
| RL RLFTFRelief Therapeutics | $0.27-17.2% | $3.3M | 1 assetsStage unavailable | No dated catalyst |
| RL RLMDRelmada Therapeutics | $4.63-0.2% | $493.9M | 5 assetsStage unavailable | No dated catalyst |
| RL RLYBRallybio | $16.83+1.4% | $89.4M | 3 assetsStage unavailable | No dated catalyst |
| RM RMTIRockwell Medical | $8.10+6.0% | $32.6M | 2 assetsStage unavailable | No dated catalyst |
| RN RNAAtrium Therapeutics | $13.20-2.1% | $225.8M | 1 assetsStage unavailable | No dated catalyst |
| RN RNACCartesian Therapeutics | $10.04-1.9% | $303.8M | 8 assetsPhase 3 | Descartes-08Phase 3 · Data readout |
| RN RNAZTransCode Therapeutics | $2.87-3.4% | $3.0M | 1 assetsStage unavailable | No dated catalyst |
| RN RNTXRein Therapeutics | $0.82+3.1% | $70.6M | 5 assetsPhase 2 | LTI-03Phase 2 · Data readout |
| RO ROIVRoivant | $36.30-1.5% | $26.22B | 14 assetsPDUFA | Brepocitinib PDUFA · Approval decision |
| RP RPTXRepare Therapeutics | $2.65+0.0% | $114.2M | 8 assetsPhase 1 | RP-1664 Phase 1 · Data readout |
| RV RVMDRevolution Medicines Inc | $209.46-1.1% | $44.89B | 16 assetsPhase 1/2 | No dated catalyst |
| RV RVNCRevance Therapeutics | $3.65+0.0% | $381.0M | 4 assetsStage unavailable | No dated catalyst |
| RV RVPHReviva Pharmaceuticals Holdings | $0.48-1.4% | $6.3M | 2 assetsStage unavailable | No dated catalyst |
| RV RVVTFRevive Therapeutics | $0.02-14.3% | $7.8M | 1 assetsStage unavailable | No dated catalyst |
| RX RXRXRecursion Pharmaceuticals | $3.50+4.8% | $1.88B | 12 assetsPhase 2 | REC-4881 Phase 2 · Data readout |
| RY RYTMRhythm Pharmaceuticals | $110.00+1.0% | $7.57B | 10 assetsApproved | No dated catalyst |
| RY RYZBRayzeBio | $62.49+0.0% | $3.72B | 2 assetsStage unavailable | No dated catalyst |
| RZ RZLTRezolute Bio | $5.09+9.2% | $490.1M | 2 assetsPhase 3 | ErsodetugPhase 3 · Data readout |
| SA SABSSAb Biotherapeutics | $3.78+2.2% | $343.9M | 2 assetsPhase 2b | SAB-142Phase 2b · Data readout |